Open Access
Cysteine 230 Is Essential for the Structure and Activity of the Cytotoxic Ligand TRAIL
2
Laboratoire Cantonal, CH-1066 Epalinges, Switzerland
|
Publication type: Journal Article
Publication date: 2000-07-01
scimago Q1
wos Q2
SJR: 1.705
CiteScore: 7.6
Impact factor: 3.9
ISSN: 00219258, 1083351X
PubMed ID:
10748154
Biochemistry
Molecular Biology
Cell Biology
Abstract
Unlike other tumor necrosis factor family members, the cytotoxic ligand tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)/Apo-2L contains an unpaired cysteine residue (Cys230) in its receptor-binding domain. Here we show that the biological activity of both soluble recombinant TRAIL and cell-associated, full-length TRAIL is critically dependent on the presence of Cys230. Mutation of Cys230 to alanine or serine strongly affected its ability to kill target cells. Binding to its receptors was decreased by at least 200-fold, and the stability of its trimeric structure was reduced. In recombinant TRAIL, Cys230 was found engaged either in interchain disulfide bridge formation, resulting in poorly active TRAIL, or in the chelation of one zinc atom per TRAIL trimer in the active, pro-apoptotic form of TRAIL.
Found
Nothing found, try to update filter.
Found
Nothing found, try to update filter.
Top-30
Journals
|
1
2
3
4
5
|
|
|
Vitamins and Hormones
5 publications, 4.63%
|
|
|
Cancers
4 publications, 3.7%
|
|
|
Molecular Cancer Therapeutics
4 publications, 3.7%
|
|
|
Cell Death and Differentiation
3 publications, 2.78%
|
|
|
Developmental and Comparative Immunology
3 publications, 2.78%
|
|
|
Cancer Research
3 publications, 2.78%
|
|
|
Current Opinion in Structural Biology
2 publications, 1.85%
|
|
|
Drug Resistance Updates
2 publications, 1.85%
|
|
|
Journal of Biological Chemistry
2 publications, 1.85%
|
|
|
Cell Death and Disease
2 publications, 1.85%
|
|
|
Applied Microbiology and Biotechnology
2 publications, 1.85%
|
|
|
Scientific Reports
2 publications, 1.85%
|
|
|
Biotechnology Letters
2 publications, 1.85%
|
|
|
Oncogene
2 publications, 1.85%
|
|
|
BMC Cancer
2 publications, 1.85%
|
|
|
PLoS ONE
2 publications, 1.85%
|
|
|
Journal of Clinical Oncology
2 publications, 1.85%
|
|
|
Journal of Immunology
1 publication, 0.93%
|
|
|
Protein and Peptide Letters
1 publication, 0.93%
|
|
|
Molecular Cell Biology Research Communications
1 publication, 0.93%
|
|
|
Neoplasia
1 publication, 0.93%
|
|
|
Trends in Biochemical Sciences
1 publication, 0.93%
|
|
|
Cell
1 publication, 0.93%
|
|
|
Cytokine and Growth Factor Reviews
1 publication, 0.93%
|
|
|
Oncotarget
1 publication, 0.93%
|
|
|
Human and Experimental Toxicology
1 publication, 0.93%
|
|
|
Technology in Cancer Research and Treatment
1 publication, 0.93%
|
|
|
Antibodies
1 publication, 0.93%
|
|
|
Cells
1 publication, 0.93%
|
|
|
1
2
3
4
5
|
Publishers
|
5
10
15
20
25
30
35
|
|
|
Elsevier
33 publications, 30.56%
|
|
|
Springer Nature
29 publications, 26.85%
|
|
|
Wiley
11 publications, 10.19%
|
|
|
American Association for Cancer Research (AACR)
8 publications, 7.41%
|
|
|
MDPI
6 publications, 5.56%
|
|
|
American Chemical Society (ACS)
3 publications, 2.78%
|
|
|
American Society for Biochemistry and Molecular Biology
2 publications, 1.85%
|
|
|
SAGE
2 publications, 1.85%
|
|
|
Public Library of Science (PLoS)
2 publications, 1.85%
|
|
|
American Society of Clinical Oncology (ASCO)
2 publications, 1.85%
|
|
|
The American Association of Immunologists
1 publication, 0.93%
|
|
|
Bentham Science Publishers Ltd.
1 publication, 0.93%
|
|
|
Impact Journals
1 publication, 0.93%
|
|
|
Federation of American Societies for Experimental Biology (FASEB)
1 publication, 0.93%
|
|
|
Taylor & Francis
1 publication, 0.93%
|
|
|
American Association for the Advancement of Science (AAAS)
1 publication, 0.93%
|
|
|
American Physiological Society
1 publication, 0.93%
|
|
|
American Society of Hematology
1 publication, 0.93%
|
|
|
Autonomous Non-profit Organization Editorial Board of the journal Uspekhi Khimii
1 publication, 0.93%
|
|
|
5
10
15
20
25
30
35
|
- We do not take into account publications without a DOI.
- Statistics recalculated weekly.
Are you a researcher?
Create a profile to get free access to personal recommendations for colleagues and new articles.
Metrics
108
Total citations:
108
Citations from 2024:
3
(2%)
Cite this
GOST |
RIS |
BibTex |
MLA
Cite this
GOST
Copy
Bodmer J. et al. Cysteine 230 Is Essential for the Structure and Activity of the Cytotoxic Ligand TRAIL // Journal of Biological Chemistry. 2000. Vol. 275. No. 27. pp. 20632-20637.
GOST all authors (up to 50)
Copy
Bodmer J., Meier P., Tschopp J., Schneider P. Cysteine 230 Is Essential for the Structure and Activity of the Cytotoxic Ligand TRAIL // Journal of Biological Chemistry. 2000. Vol. 275. No. 27. pp. 20632-20637.
Cite this
RIS
Copy
TY - JOUR
DO - 10.1074/jbc.M909721199
UR - https://doi.org/10.1074/jbc.M909721199
TI - Cysteine 230 Is Essential for the Structure and Activity of the Cytotoxic Ligand TRAIL
T2 - Journal of Biological Chemistry
AU - Bodmer, Jean-Luc
AU - Meier, Pierre
AU - Tschopp, Jürg
AU - Schneider, Pascal
PY - 2000
DA - 2000/07/01
PB - American Society for Biochemistry and Molecular Biology
SP - 20632-20637
IS - 27
VL - 275
PMID - 10748154
SN - 0021-9258
SN - 1083-351X
ER -
Cite this
BibTex (up to 50 authors)
Copy
@article{2000_Bodmer,
author = {Jean-Luc Bodmer and Pierre Meier and Jürg Tschopp and Pascal Schneider},
title = {Cysteine 230 Is Essential for the Structure and Activity of the Cytotoxic Ligand TRAIL},
journal = {Journal of Biological Chemistry},
year = {2000},
volume = {275},
publisher = {American Society for Biochemistry and Molecular Biology},
month = {jul},
url = {https://doi.org/10.1074/jbc.M909721199},
number = {27},
pages = {20632--20637},
doi = {10.1074/jbc.M909721199}
}
Cite this
MLA
Copy
Bodmer, Jean-Luc, et al. “Cysteine 230 Is Essential for the Structure and Activity of the Cytotoxic Ligand TRAIL.” Journal of Biological Chemistry, vol. 275, no. 27, Jul. 2000, pp. 20632-20637. https://doi.org/10.1074/jbc.M909721199.